Business
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately – BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effecti
About this update from Tango Therapeutics, Inc.
[{"type":"image","alt":"Tango Therapeutics Sub, Inc","displaySize":"","headline":null,"caption":"Tango Therapeutics Sub, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/c3de9171edd0bb03873b0a60a69fc0f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gnbHKADQpfb1RiB2aEmYUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c3de9171edd0bb03873b0a60a69fc0f6","width":300,"height":120}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately –","length":114,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":198,"olType":false},{"type":"text","content":"BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company’s founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience and who has served on the Tango Board of Directors since 2018, who will drive the next phase of company growth.","length":693,"tagName":"p"},{"type":"text","content":"In her new capacity as Executive Chair, Dr. Weber will remain closely involved with the senior management team of Tango, supporting the company’s strategic priorities and working with Dr. Peters to ensure a seamless transition and continued clinical execution throughout 2026. Alexis Borisy, the current Board Chair, will transition to Lead Independent Director.","length":362,"tagName":"p"},{"type":"text","content":"“It has been an extraordinary privilege to build and lead Tango from its inception,” said Barbara Weber, M.D., Executive Chair of Tango Therapeutics. “I am incredibly proud of what the team has accomplished in the last eight years as we le...